How one start­up fore­told the neu­ro­science re­nais­sance af­ter '50 years of shit­show'

In the past cou­ple of years, some­thing cu­ri­ous has hap­pened: Phar­ma and VC dol­lars start­ed gush­ing in­to neu­ro­science re­search.

Bio­gen’s con­tro­ver­sial new Alzheimer’s drug Aduhelm has been ap­proved on the ba­sis of re­mov­ing amy­loid plaque from the brain, but the new neu­ro-fo­cused phar­ma and biotechs have much lofti­er aims. Sig­nif­i­cant­ly curb­ing or even cur­ing the most no­to­ri­ous dis­or­ders would prove the Holy Grail for a com­plex sys­tem that has tied the world’s best drug de­vel­op­ers in knots for decades.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER